Logomix offers a Geno-Writing platform that enables precise engineering of megabase-scale genomic sequences in human cells, facilitating the creation of custom cell types with specific functions. This technology addresses the challenges of immune rejection and functional integration in cell therapies, enhancing the development of advanced regenerative medicine solutions.
Funding
$3.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
ABFounders
Product
Problem
Current cell therapies face challenges with immune rejection and achieving functional integration of engineered cells within the host tissue. Engineering large-scale genomic sequences in human cells to create custom cell types with specific functions remains a complex and inefficient process.
Solution
Logomix offers a Geno-Writing platform designed for precise engineering of megabase-scale genomic sequences in human cells. This platform facilitates the creation of custom cell types with specific functions, addressing critical challenges in cell therapy development. By enabling large-scale genomic alterations, the Geno-Writing platform enhances control over rejection responses and improves the integration of new functions into cells. This technology aims to simplify the design and reconstitution of induced pluripotent stem cell (iPSC) genomes, making it easier to control rejection responses and install desired functions into master cells.
Target Audience
The primary target audience includes researchers and companies involved in cell therapy development and regenerative medicine, particularly those focused on iPSC-derived therapies.
Features
- Geno-Writing platform for large-scale genomic alterations in cells
- Ability to create new cell types with desired functions
- Targeted HLA-I and HLA-II biallelic deletion capabilities
- Site-specific integration of UKiS landing pads
- Chimeric HLA-A/E monoallelic expression